Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,666 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW; CADILLAC Investigators. Tcheng JE, et al. Among authors: stone gw. Circulation. 2003 Sep 16;108(11):1316-23. doi: 10.1161/01.CIR.0000087601.45803.86. Epub 2003 Aug 25. Circulation. 2003. PMID: 12939213 Clinical Trial.
Influence of acute myocardial infarction location on in-hospital and late outcome after primary percutaneous transluminal coronary angioplasty versus tissue plasminogen activator therapy.
Stone GW, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, Hartzler GO, Overlie P, Donohue B, Chelliah N, Vlietstra R, Puchrowicz-Ochocki S, O'Neill WW. Stone GW, et al. Am J Cardiol. 1996 Jul 1;78(1):19-25. doi: 10.1016/s0002-9149(96)00220-2. Am J Cardiol. 1996. PMID: 8712112 Clinical Trial.
Outcome of different reperfusion strategies in patients with former contraindications to thrombolytic therapy: a comparison of primary angioplasty and tissue plasminogen activator. Primary Angioplasty in Myocardial Infarction (PAMI) Investigators.
Stone GW, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe JH, Hartzler GO, Overlie P, Donohue B, Chelliah N, Vlietstra R, Puchrowicz-Ochocki S, O'Neill WW. Stone GW, et al. Cathet Cardiovasc Diagn. 1996 Dec;39(4):333-9. doi: 10.1002/(SICI)1097-0304(199612)39:4<333::AID-CCD1>3.0.CO;2-E. Cathet Cardiovasc Diagn. 1996. PMID: 8958418 Clinical Trial.
Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators.
Stone GW, Grines CL, Rothbaum D, Browne KF, O'Keefe J, Overlie PA, Donohue BC, Chelliah N, Vlietstra R, Catlin T, O'Neill WW. Stone GW, et al. J Am Coll Cardiol. 1997 Apr;29(5):901-7. doi: 10.1016/s0735-1097(97)00041-7. J Am Coll Cardiol. 1997. PMID: 9120173 Free article. Clinical Trial.
A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. Second Primary Angioplasty in Myocardial Infarction (PAMI-II) Trial Investigators.
Stone GW, Marsalese D, Brodie BR, Griffin JJ, Donohue B, Costantini C, Balestrini C, Wharton T, Esente P, Spain M, Moses J, Nobuyoshi M, Ayres M, Jones D, Mason D, Grines L, O'Neill WW, Grines CL. Stone GW, et al. J Am Coll Cardiol. 1997 Jun;29(7):1459-67. doi: 10.1016/s0735-1097(97)00088-0. J Am Coll Cardiol. 1997. PMID: 9180105 Free article. Clinical Trial.
Primary coronary angioplasty versus thrombolysis.
Stone GW, Grines CL, O'Neill WW. Stone GW, et al. N Engl J Med. 1997 Oct 16;337(16):1168-9; author reply 1170. doi: 10.1056/NEJM199710163371612. N Engl J Med. 1997. PMID: 9340505 No abstract available.
1,666 results